15225834

Source:http://linkedlifedata.com/resource/pubmed/id/15225834

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0015264, umls-concept:C0086045, umls-concept:C0249582, umls-concept:C0282549, umls-concept:C0441655, umls-concept:C1533691
pubmed:issue	1-5
pubmed:dateCreated	2004-6-30
pubmed:abstractText	19-Nor-1alpha,25-dihydroxyvitamin D2 (paricalcitol) is an analogue of 1,25(OH)2D3 with reduced calcemic effects that is approved in the United States for the suppression of parathyroid hormone in chronic renal failure. Paricalcitol has anticancer activity in prostate cancer cells. We tested the effects of paricalcitol on the HL-60 leukemia cells, studying cellular differentiation, cell cycle changes, apoptosis and cellular proliferation. Paricalcitol at 10(-8)M concentration induced the maturation of HL-60 cells in a time-dependent manner, as shown by increased expression of CD11b differentiation surface antigen. The ability of HL-60 cells to reduce nitroblue tetrazolium (NBT) was markedly increased after exposure to paricalcitol at 10(-8)M for 72 h. Paricalcitol inhibited colony formation of HL-60 cells in a soft agar semisolid media after 10-day incubation (estimated IC50 of 5 x 10(-9) M. Exposure to 10(-8)M paricalcitol for 72 h increased the number of cells in G0/G1 phase, and decreased the number of cells in S phase, and significantly increased the number of HL-60 cells undergoing apoptosis. The concentration required to achieve inhibition of growth of HL-60 cells is comparable to clinically achievable levels. These findings support the clinical evaluation of paricalcitol as an antileukemia agent.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9015483
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/19-nor-1,24,25-trihydroxyvitamin D2, http://linkedlifedata.com/resource/pubmed/chemical/Ergocalciferols
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	0960-0760
pubmed:author	pubmed-author:KuteTimothyT, pubmed-author:MolnárIstvánI, pubmed-author:SchwartzGary GGG, pubmed-author:WillinghamMark CMC
pubmed:issnType	Print
pubmed:volume	89-90
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	539-43
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:15225834-Apoptosis, pubmed-meshheading:15225834-Cell Cycle, pubmed-meshheading:15225834-Cell Division, pubmed-meshheading:15225834-Ergocalciferols, pubmed-meshheading:15225834-HL-60 Cells, pubmed-meshheading:15225834-Humans
pubmed:year	2004
pubmed:articleTitle	19-Nor-1alpha,25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations.
pubmed:affiliation	Section on Hematology and Oncology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't